Clinical implications of systemic and local immune responses in human angiosarcoma

Angiosarcomas are a rare subtype of soft-tissue sarcomas which exhibit aggressive clinical phenotypes with limited treatment options and poor outcomes. In this study, we investigated the clinical relevance of the peripheral blood neutrophil-to-lymphocyte ratio (NLR) as a marker of systemic immune response, as well as its correlation with intra-tumoral immune profiles in a subgroup of cases (n=35) using the NanoString PanCancer IO360 panel and multiplex immunohistochemistry. In the overall cohort (n=150), angiosarcomas of the head and neck (AS-HN) comprised most cases (58.7%) and median overall survival (OS) was 1.1 year. NLR, classified as high in 78 of 112 (70%) evaluable patients, was independently correlated with worse OS (HR 1.84, 95%CI 1.18-2.87, p=0.0073). Peripheral blood NLR was positively correlated with intra-tumoral NLR (tNLR) (Spearman's rho 0.450, p=0.0067). Visualization of tumor-infiltrating immune cells confirmed that tNLR scores correlated directly with both neutrophil (CD15(+) cells, rho 0.398, p=0.0198) and macrophage (CD68(+) cells, rho 0.515, p=0.0018) cell counts. Interestingly, tNLR correlated positively with oncogenic pathway scores including angiogenesis, matrix remodeling and metastasis, and cytokine and chemokine signaling, as well as myeloid compartment scores (all p<0.001). In patients with documented response assessment to first-line chemotherapy, these pathway scores were all significantly higher in non-responders (47%) compared to responders. In conclusion, systemic and local immune responses may inform chemotherapy response and clinical outcomes in angiosarcomas.

Automated summary

This study found a correlation between peripheral blood neutrophil-to-lymphocyte ratio (NLR) and intra-tumoral immune profiles in angiosarcomas, with higher NLR associated with worse overall survival. Additionally, high NLR was positively correlated with oncogenic pathway scores in the tumor microenvironment, suggesting a potential link between systemic and local immune responses and chemotherapy outcomes in these patients.